Chiricozzi A, Burlando M, Caldarola G, et al. - In a cohort of psoriatic and psoriatic arthritis individuals, researchers conducted this multicenter, retrospective observational study to test the safety and efficacy of ixekizumab (anti-IL-17A). The sample consisted of 201 individuals affected by moderate-to-severe psoriasis and treated with ixekizumab at seven Italian University centers. Data analysis concentrated on 110 participants who began ixekizumab at baseline and completed at least 24 weeks of treatment. According to findings, significant decrease of mean (± standard deviation) baseline Psoriasis Area Severity Index score was identified at 4 weeks of ixekizumab therapy, with further significant improvement at weeks 12 and 24. This research shows ixekizumab in clinical practice in the real world, demonstrating its effectiveness and protection in psoriasis and psoriatic arthritis treatment.